Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes

Leukemia Research

Volumn 31, Issue SUPPL. 3, 2007, Pages

  Goldberg, Stuart L ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiac iron overload; Clinical efficacy; Deferasirox; Myelodysplastic syndromes; Oral iron chelating agent; Transfusional iron overload

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ARTHRALGIA; ARTHROPATHY; CHELATION THERAPY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; EYE DISEASE; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEART MUSCLE CONTRACTILITY; HUMAN; HYPOACUSIS; IRON CHELATION; IRON OVERLOAD; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; PATIENT SATISFACTION; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; THALASSEMIA MAJOR; THROMBOCYTOPENIA;

BENZOIC ACIDS; BLOOD TRANSFUSION; DRUG TOXICITY; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES; PYRIDONES; SURVIVAL RATE; TREATMENT OUTCOME; TRIAZOLES;

EID: 36248970725     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(07)70462-9     Document Type: Review

References (35)

1. Greenberg P., Cox C., LeBeau M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
2. Brechignac S., Hellstrom-Lindberg E., Bowen D., DeWitte T., Cazzola M., and Fenaux P. Quality of life and economic impact of red blood cell (RBC) transfusions on patients with myelodysplastic syndromes (MDS). Blood (ASH Annual Meeting Abstracts) 104 (2004) Abstract 4716.
3. Malcovati L., Porta M., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23 (2005) 7594-7603
4. Malcovati L., Germing U., Kuendgen A., Della Porta M., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25 (2007) 3503-3510
5. Deschler B., de Witte T., Mertelsmann R., and Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 91 (2006) 1513-1522
6. Goldberg S., Mody-Patel N., and Warnock N. P001: Incidence of myelodysplastic syndromes in the United States medicare population. Leuk Res 31 Suppl 1 (2007) S41
7. Chacko J., Pennell D., Tanner M., Hamblin T., Wonke B., Levy T., et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 138 (2007) 587-593
8. Konen E., Ghoti H., Goitein O., Winder A., Kushnir T., Eshet Y., et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique. Am J Hematol 82 (2007) 1013-1016
9. Leitch H., Goodman T., Wong K., Vickars L., Galbraith P., and Leger C. Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy. Blood (ASH Annual Meeting Abstracts) 108 (2006) Abstract 249.
10. Bennett J., and List A. Disparities in criteria for initiating chelation therapy for iron overload in patients with myelodysplastic syndromes (MDS). Blood 106 (2005) Abstract 2535.
11. Olivieri N., and Brittenham G. Iron-chelating therapy and the treatment of thalassemia. Blood 89 (1997) 739-761
12. Novartis Pharmaceuticals Pharmaceuticals. Desferal® (deferoxamine) package insert, 2002.
13. Kushner J., Porter J., and Olivieri N. Secondary iron overload. Hematology Am Soc Hematol Educ Program (2001) 47-61
14. Apotex Europe Ltd. Ferriprox® (deferiprone) package insert, 1999.
15. Cappellini M., Cohen A., Piga A., Bejaoui M., Perrotta S., Agaoglu L., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107 (2006) 3455-3462
16. Novartis Pharmaceuticals. Exjade® (deferasirox) package insert, 2005.
17. Olivieri N., Brittenham G., McLaren C., Templeton D., Cameron R., McClelland R., et al. Long-term safety and effectiveness of iron- chelation therapy with deferiprone for thalassemia major. N Engl J Med 339 (1998) 417-423
18. Tanner M., Galanello R., Dessi C., Smith G., Westwood M., Agus A., et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115 (2007) 1876-1884
19. Cohen A., Galanello R., Piga A., De Sanctis V., and Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102 (2003) 1583-1587
20. Kersten M., Lange R., Smeets M., Vreugdenhil G., Roozendaal K., Lameijer W., et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol 73 (1996) 247-252
21. Nick H., Acklin P., Lattmann R., Buehlmayer P., Hauffe S., Schupp J., et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 10 (2003) 1065-1076
22. Galanello R., Piga A., Alberti D., Rouan M., Bigler H., and Séchaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 43 (2003) 565-572
23. Piga A., Galanello R., Forni G., Cappellini M., Origa R., Zappu A., et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91 (2006) 873-880
24. Porter J., Borgna-Pignatti C., Baccarani M., Saviano A., Abish S., Malizia R., et al. Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis. Blood (ASH Annual Meeting Abstracts) 106 (2005) Abstract 2690.
25. Porter J., Galanello R., Saglio G., Neufeld E., Vichinsky E., Cappellini M., et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-year prospective study. Eur J Haematol (2007) Online-Accepted Articles. Accepted article online: 26-Oct-2007. doi: 10.1111/j.1600-0609.2007.00985.
26. Cazzola M., Gattermann N., Greenberg P., Maertens J., Soulieres D., Rose C., et al. ICL670, a once-daily oral iron chelator, is effective and well tolerated in patients with myelodysplastic syndrome (MDS) and iron overload. Haematologica 90 Suppl 2 (2005) 306
27. Vichinsky E., Onyekwere O., Porter J., Swerdlow P., Eckman J., Lane P., et al., Deferasirox in Sickle Cell Investigators. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 136 3 (2007) 501-508
28. List A., Esposito J., Decker J., Baer M., Powell B., Steensma D., et al. Iron parameters in 84 MDS patients enrolled in a deferasirox (Exjade®, ICL670) multicenter trial. Blood (ASH Annual Meeting Abstracts) 108 (2006) Abstract 4847.
29. Gattermann N., Schmid M., Vassilieff D., Rose C., Della Porta M., Finelli C., et al. P129: Severe iron overload in patients with myelodysplastic syndromes (MDS) enrolled in a large study of deferasirox (Exjade®, ICL670). Leuk Res 31 Suppl 1 (2007) S109-S110
30. Cabantchik Z., Link G., Glickstein H., Ben El R., Hershko C., Konijn A., et al. Deferasirox (Exjade®, ICL670): a journey into labile iron centers of living cardiomyocytes. Blood (ASH Annual Meeting Abstracts) 106 (2005) Abstract 824.
31. Glickstein H., Ben El R., Link G., Breuer W., Konijn A., Hershko C., et al. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Blood 108 (2006) 3195-3203
32. Wood J., Otto-Duessel M., Gonzalez I., Aguilar M., Shimada H., Nick H., et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res 148 (2006) 272-280
33. Porter J., Tanner M., Pennell D., and Eleftheriou P. Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (deferasirox). Blood (ASH Annual Meeting Abstracts) 106 (2005) Abstract 3600.
34. Gattermann N., Zoumbos N., Angelucci E., Drelichman G., Siegel J., Glimm E., et al. Impact on iron removal of dose reduction for non- progressive serum creatinine increases during treatment with the once- daily, oral iron chelator deferasirox (Exjade®, ICL670). Blood (ASH Annual Meeting Abstracts) 108 (2006) Abstract 3824.
35. Cappellini M., Bejaoui M., Agaoglu L., Porter J., Coates T., Jeng M., et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 29 5 (2007) 909-917